Stockscreener 앱 받기
4.00
3.90%
0.15
시장 영업 전:
4.04
0.04
+1.00%
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
AtaiBeckley (ATAI) Reports Phase 2a Data in CNS Drugs - MSN
HC Wainwright bullish on AtaiBeckley (ATAI) - MSN
Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers like AtaiBeckley - Proactive financial news
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - National Today
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences - GlobeNewswire Inc.
Positive Phase 2a TRD Data For BPL-003 Might Change The Case For Investing In AtaiBeckley (ATAI) - simplywall.st
5 Stocks Under $5 That Will Explode - insidermonkey.com
AtaiBeckley (HAM:9VC) Cyclically Adjusted Price-to-FCF : (As of Apr. 11, 2026) - GuruFocus
Psychedelic: AtaiBeckley reports publication of BPL-003 study results - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT) - The Globe and Mail
AtaiBeckley Depression Drug Delivers Rapid Day-2 Antidepressant Response - Sahm
Ataibeckley depression drug delivers rapid day-2 antidepressant response - MSN
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD (NASDAQ:ATAI) - Seeking Alpha
Small cap wrap: AtaiBeckley, EDM Resources, Genflow Biosciences… - Proactive financial news
AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 - Yahoo! Finance Canada
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - Investing News Network
AtaiBeckley's BPL-003 May Lay the Foundation for a Scalable Mental Health System—The Outcome of 2026 Phase 3 Studies Will Determine Its Future - Bitget
AtaiBeckley reports positive phase 2a data for depression drug - Investing.com
AtaiBeckley Announces Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression with FDA Breakthrough Therapy Designation - Quiver Quantitative
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs - The Manila Times
AtaiBeckley reports positive phase 2a data for depression drug By Investing.com - Investing.com UK
AtaiBeckley (ATAI) Valuation Check After Earnings Beat And Mental Health Pipeline Progress - simplywall.st
Deutsche Bank confident of AtaiBeckley Inc. (ATAI) growth prospects on psychedelic medicines - MSN
Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines - Insider Monkey
AtaiBeckley Inc. (ATAI) latest stock news and headlines - Yahoo Finance Singapore
Why AtaiBeckley (ATAI) Is Up 13.1% After Deutsche Bank Highlights Its Post-Merger Pipeline Potential - simplywall.st
AtaiBeckley Inc. (B72.DE) - Yahoo! Finance Canada
ATAI Stock Price, Quote & Chart | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Deutsche Bank initiates bullish coverage of psychedelics company AtaiBeckley - Mugglehead Investment Magazine
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart - Capital.com
Over-the-top psychedelic promos could undermine the field’s drug development efforts - statnews.com
AtaiBeckley Inc (ATAI) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Is Ataibeckley Inc (ATAI) looking to sell its flagship psychedelic drug candidate BPL-003? - MSN
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
Is It Time To Reassess AtaiBeckley (ATAI) After Its Recent Share Price Slide? - simplywall.st
AtaiBeckley Weighs BPL-003 Deal After Strong Phase 2a And FDA Support - Yahoo Finance
Is Psychedelic Nasal Spray Data And Index Inclusion Altering The Investment Case For AtaiBeckley (ATAI)? - simplywall.st
Deutsche Bank initiates coverage of AtaiBeckley (ATAI) with buy recommendation - MSN
AtaiBeckley Inc. Trade Ideas — TRADEGATE:B72 - TradingView
AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts - Yahoo! Finance Canada
AtaiBeckley initiated with a Buy at Deutsche Bank - TipRanks
Deutsche Bank Initiates AtaiBeckley at Buy With $12 Price Target - MarketScreener
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential - Investing.com India
Deutsche Bank Initiates AtaiBeckley(ATAI.US) With Buy Rating, Announces Target Price $12 - Moomoo
Deutsche Bank initiates Atai Life Sciences stock at buy on psychedelic therapy potential By Investing.com - Investing.com South Africa
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - MSN
2.69%
0.25%
자본화:
|
볼륨(24시간):